Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R2 | Q9NPC1 | 10/20 | 0.49 |
| ▸ | AGTR1 | P30556 | 12/20 | 0.48 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.46 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.46 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3423 | 0.99 | LTB4R2 (0.49) | LTB4R2AGTR1ABCB11GP6AGTR2 | |
| SCHEMBL8485020 | 0.92 | LTB4R2 (0.41) | LTB4R2AGTR1ABCB11GP6 | |
| SCHEMBL3077 | 0.91 | LTB4R2 (0.44) | LTB4R2AGTR1ABCB11GP6AGTR2 | |
| SCHEMBL8485466 | 0.91 | LTB4R2 (0.42) | LTB4R2AGTR1ABCB11GP6 | |
| SCHEMBL1993 | 0.90 | LTB4R2 (0.45) | LTB4R2AGTR1ABCB11GP6AGTR2 | |
| SCHEMBL3104 | 0.85 | AGTR1 (0.50) | LTB4R2AGTR1ABCB11GP6 | |
| SCHEMBL8474590 | 0.85 | AGTR1 (0.43) | LTB4R2AGTR1ABCB11GP6 | |
| SCHEMBL8481903 | 0.85 | PTGDR2 (0.38) | LTB4R2AGTR1ABCB11GP6 | |
| Abitesartan SCHEMBL2527 | 0.84 | AGTR1 (0.51) | LTB4R2AGTR1ABCB11GP6 | |
| SCHEMBL8483198 | 0.84 | PTGDR2 (0.38) | LTB4R2AGTR1ABCB11GP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0443983-B1 | Acyl compounds | CIBA GEIGY AG (CH) | 1996-02-28 | — | — | EP | claimed |
| EP-0443983-A1 | Acyl compounds | CIBA-GEIGY AG (CH) | 1991-08-28 | — | — | EP | claimed |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | BRAINCELLS INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | BRAINCELLS INC. (US) | 2011-02-24 | — | — | US | disclosed |
| EP-0443983-B1 | Acyl compounds | CIBA GEIGY AG (CH) | 1996-02-28 | — | — | EP | disclosed |
| US-5399578-A | Hypotensive; valsartan; high blood pressure and cardiac insufficiency | CIBA-GEIGY CORP (US) | 1995-03-21 | — | — | US | disclosed |
| EP-0443983-A1 | Acyl compounds | CIBA-GEIGY AG (CH) | 1991-08-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | GAP43, GABRB1, GABRB3 | LTB4R2 609/4885AGTR1 3252/4885ABCB11 4659/4885 |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | NGF, DCX, BDNF | LTB4R2 254/4885AGTR1 8/4885ABCB11 4566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.